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In their Snapshot, Tapper, Robson, and Malik suggest that circu-
lating platelet-derived microparticles are increased in cirrhosis
as a function of systemic inﬂammation [1]. Ogasawara and col-
leagues observed higher levels of circulating platelet microparti-
cles in 22 patients with cirrhosis as compared to 17 healthy
controls [2]. However, the results of two other independent stud-
ies assessing circulating platelet microparticle levels in patients
with cirrhosis do not concur. Sayed and colleagues included 60
patients with hepatitis C related cirrhosis and 20 healthy controls
[3]. Platelet microparticle levels, expressed as a percentage of the
total platelet count, were not different between patients with cir-
rhosis and controls [3]. When calculating their circulating con-
centration, one can conclude that the platelet microparticle
level was even lower in patients with cirrhosis than in controls
(14.2  109/L vs. 36.5  109/L, respectively). Our group also did
not observe any difference in circulating levels of platelet micro-
particles between 26 patients with cirrhosis and 30 healthy con-
trols [4]. In addition, there was no correlation between
circulating levels of platelet derived microparticles (CD41+) and
inﬂammatory markers, either in the pilot cohort (C-reactive pro-
tein: Spearman correlation coefﬁcient = 0.412, p = 0.071, n = 20;
leukocytes: Spearman correlation coefﬁcient = 0.272, p = 0.179,
n = 26) or in the additional cohort (C-reactive protein: Spearman
correlation coefﬁcient = 0.211, p = 0.129, n = 53; leukocytes:
Spearman correlation coefﬁcient = 0.068, p = 0.597, n = 63).
Therefore, the currently available data demonstrate that platelet
derived microparticles are not systematically increased in
patients with cirrhosis and likely do not contribute to the proco-
agulant imbalance associated with cirrhosis.
Certain subpopulations of microparticles also express tissue
factor, the primary initiator of coagulation, at their surface. These
microparticles are highly procoagulant [5]. Platelets are not a
major source of tissue factor positive microparticles in healthy
individuals and patients [6]. It remains to be determined whether
these circulating tissue factor positive microparticles are
increased in patients with cirrhosis and contribute to the proco-
agulant imbalance in this setting.ncial support
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